Amphastar Pharmaceuticals 

$18.85
284
+$0.44+2.39% Today

Statistics

Day High
18.89
Day Low
18.45
52W High
30.81
52W Low
16.87
Volume
1,345,281
Avg. Volume
-
Mkt Cap
855.22M
P/E Ratio
11.09
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
0.42
0.61
0.8
0.99
Expected EPS
0.691429
Actual EPS
N/A

Financials

13.63%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.44BRevenue
196.19MNet Income

Analyst Ratings

21.25Average Price Target
The highest estimate is 23.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMPH. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Show more...
CEO
Dr. Ziping Luo Ph.D.
Employees
2028
Country
United States
ISIN
US03209R1032

Listings

0 Comments

Share your thoughts

FAQ

What is Amphastar Pharmaceuticals stock price today?
The current price of AMPH is $18.85 USD — it has increased by +2.39% in the past 24 hours. Watch Amphastar Pharmaceuticals stock price performance more closely on the chart.
What is Amphastar Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amphastar Pharmaceuticals stocks are traded under the ticker AMPH.
Is Amphastar Pharmaceuticals stock price growing?
AMPH stock has risen by +5.67% compared to the previous week, the month change is a -12.05% fall, over the last year Amphastar Pharmaceuticals has showed a -23.05% decrease.
What is Amphastar Pharmaceuticals market cap?
Today Amphastar Pharmaceuticals has the market capitalization of 855.22M
When is the next Amphastar Pharmaceuticals earnings date?
Amphastar Pharmaceuticals is going to release the next earnings report on August 10, 2026.
What were Amphastar Pharmaceuticals earnings last quarter?
AMPH earnings for the last quarter are 0.42 USD per share, whereas the estimation was 0.71 USD resulting in a -40.44% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amphastar Pharmaceuticals revenue for the last year?
Amphastar Pharmaceuticals revenue for the last year amounts to 1.44B USD.
What is Amphastar Pharmaceuticals net income for the last year?
AMPH net income for the last year is 196.19M USD.
How many employees does Amphastar Pharmaceuticals have?
As of May 26, 2026, the company has 2,028 employees.
In which sector is Amphastar Pharmaceuticals located?
Amphastar Pharmaceuticals operates in the Health & Wellness sector.
When did Amphastar Pharmaceuticals complete a stock split?
Amphastar Pharmaceuticals has not had any recent stock splits.
Where is Amphastar Pharmaceuticals headquartered?
Amphastar Pharmaceuticals is headquartered in Rancho Cucamonga, United States.